title: [Animal experiment, pharmacokinetic and clinical studies of intraperitoneal therapy with interleukin-2 (n Il-2) in patients with ovarian carcinoma].
abstract: OBJECTIVE
  In an orthotopic transplantation model using human ovarian cancer xenografts we evaluated antitumor effects of nIL-2 as well as its side effects in a clinical phase I/II study.
  
  
  METHODS
  In patients with advanced ovarian cancer nIL-2 was administered i.p. in escalating doses every two days by means of a Tenckhoff-catheter.
  
  
  RESULTS
  Considerable stimulation of intraperitoneal immune cells was observed without severe toxic side effect WHO grade III/IV.
  
  
  CONCLUSIONS
  Due to pharmacological-pharmacokinetic advantages using the i.p. route nIL-2 was very well tolerated and showed considerable stimulation of local immune cells.
authors.affiliation: Universitäts-Frauenklinik Aachen, FRG.
authors.forename: W
authors.initials: W
authors.lastname: Schröder
authors.forename: U
authors.initials: U
authors.lastname: Schwuléra
authors.forename: R
authors.initials: R
authors.lastname: Lissner
authors.forename: H G
authors.initials: HG
authors.lastname: Bender
mesh_terms: D000328:Adult; D000818:Animals; D010478:Chemotherapy, Cancer, Regional Perfusion; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D007111:Immunity, Cellular / Q000187:drug effects; D007274:Injections, Intraperitoneal; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D008875:Middle Aged; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*
chemical_list: D007376:Interleukin-2
vernacular_title: Tierexperimentelle, pharmakokinetische und klinische Untersuchungen zur intraperitonealen Therapie mit Interleukin-2 (n IL-2) bei Patientinnen mit Ovarialkarzinom.